Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: System Lupus Erythematosus(SLE) Clear all
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

NCT01162681
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
A-623, Placebo Comparator
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

NCT00198068
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 2Phase 3 Interventional

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

NCT00189124
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Dehydroepiandrosterone (DHEA)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Zostavax in Systemic Lupus Erythematosus

NCT01474720
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Zostavax vaccine
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 4, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Study of Lupus Patients and Their Families

NCT00235378
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
2,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 4, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus

NCT00412841
View directory record Official record
Conditions
Avascular Necrosis
Interventions
Atorvastatin, MRI, Venipuncture, Placebo
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Fontana, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Early Phase 1 Interventional

Stress, Inflammation and Immune Response Pilot Study- Aim 3

NCT04857151
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Inflammation
Interventions
App based mindfulness program (ABMP)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
38
States / cities
Beverly Hills, California • Fullerton, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus

NCT00007358
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
Interventions
Dexamethasone or other corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
4
States / cities
New Haven, Connecticut • Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 4, 2026, 10:18 PM EDT
Terminated Not applicable Interventional Results available

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting Phase 1 Interventional

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Vonsetamig, Odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

Nelfinavir in Systemic Lupus Erythematosus

NCT02066311
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Nelfinavir
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 4 Interventional

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

NCT01769937
View directory record Official record
Conditions
Lupus Erythematosus Systemic Exacerbation
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting Phase 2 Interventional

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

NCT07328581
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
Biological
Lead sponsor
iCell Gene Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Hawthorne, New York • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

NCT02119156
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Manhasset, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 4, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lupus Genetics Studies

NCT00071175
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
3,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 4, 2026, 10:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 1 Interventional

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695
View directory record Official record
Conditions
Lupus Arthritis, Systemic Lupus Erythematosus
Interventions
AMG 557, Matching Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Los Angeles, California • San Leandro, California • Danbury, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Not applicable Interventional Results available

Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology

NCT05116163
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Arthritis, Osteoarthritis
Interventions
Individuation Intervention plus implicit bias educational modules, Implicit bias educational modules
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 4, 2026, 10:18 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 10:18 PM EDT
Withdrawn Phase 2 Interventional

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

NCT00390091
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
abetimus sodium (LJP 394)
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Los Angeles, California • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 4, 2026, 10:18 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD5492
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 10:18 PM EDT